Array Biopharma, Inc. (ARRY) Posts Narrower than Expected Q1 Loss

Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.11), $0.05 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $19.1 million versus the consensus estimate of $18.51 million.

For earnings history and earnings-related data on Array Biopharma, Inc. (ARRY) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Netflix climbs following Ackman stake, up 1.8%
• Cellebrite names new CEO and cuts full-year ARR and revenue outlook
• Aptiv PLC. (APTV) PT Lowered to $64 at Argus